Transthyretin Amyloid Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Transthyretin Amyloid Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Multimodality Cardiac Imaging for Disease Progression in ATTR-CM [NA]
Clinical trial investigating multimodality cardiac imaging to track disease progression in transthyretin-related cardiac amyloidosis (ATTR-C…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis [Phase 2]
This is a Phase 2 clinical trial update for NNC6019-0001 evaluating long-term treatment in people with transthyretin amyloid cardiomyopathy …
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
A completed clinical trial in India studied Tafamidis for transthyretin amyloid cardiomyopathy. The study was sponsored by Pfizer.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A clinical trial update indicates completion of a study evaluating tafamidis 61 mg in people with transthyretin amyloid cardiomyopathy.
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: US Benchmarking Clinical Study
Sponsor eMyosound SAS reports that the US benchmarking clinical study is currently recruiting participants for conditions including heart fa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants [Phase 3]
Open-label Phase 3 safety study of Acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy participants; the trial is currentl…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Clinical trial TRACE 1 is a recruiting study that aims to phenotype and characterize wild-type transthyretin amyloid cardiomyopathy in trans…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy [Phase 1]
Phase 1 clinical trial evaluating parametric cardiac 18F-flutemetamol PET imaging in transthyretin amyloid cardiomyopathy has completed.
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.
An observational study sponsored by Yale University uses AI analyses of ECG, point-of-care ultrasound, and transthoracic echocardiography to…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating genistein for transthyretin amyloid cardiomyopathy is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Vyndaqel Capsules Special Investigation (ATTR-CM)
Pfizer reports the completion of a special investigation trial evaluating Vyndaqel (tafamidis) capsules for transthyretin amyloid cardiomyop…
-
CLINICAL_TRIALS research · 2025-05-08Clinical Trial Update: Thailand ATTR-CM Registry
A Mahidol University–sponsored clinical trial registry entry for Transthyretin amyloid cardiomyopathy (ATTR-CM) is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-18Clinical Trial Update: Exercise Training in Transthyretin Cardiac Amyloidosis [NA]
A clinical trial is currently recruiting to evaluate the effects of exercise training in patients with transthyretin-related cardiac amyloid…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy [Phase 3]
This clinical trial update reports the completion of a Phase 3 long-term safety evaluation of tafamidis in transthyretin amyloid cardiomyopa…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: carDIo-ttranSSfOrm nucLEar Imaging Study
The carDIo-ttranSSfOrm nucLEar Imaging Study, sponsored by Oregon Health and Science University, has been terminated. The study involves amy…
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Phase 4]
Pfizer completed a Phase 4 study evaluating the safety and efficacy of tafamidis in Chinese participants with transthyretin amyloid cardiomy…
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM [Phase 3]
Phase 3 trial of ALXN2060 in Japanese participants with symptomatic transthyretin amyloid cardiomyopathy has completed and results were post…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: PL_GNT01_ISR_Grant 53234273
A clinical trial update indicates that the PL_GNT01_ISR_Grant study (NCT06714019) is currently enrolling by invitation for transthyretin-rel…
-
FDA approval · 2024-11-22FDA Approved: ATTRUBY — Original Application (BridgeBio Pharma, Inc.)
The FDA approved ATTRUBY (acoramidis hydrochloride) from BridgeBio Pharma as a new treatment for transthyretin amyloid cardiomyopathy.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 [Phase 1]
Phase 1 single and multiple ascending dose study assessing safety, tolerability, PK and PD of AG10 in transthyretin amyloid cardiomyopathy; …
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery
The study aims to facilitate early diagnosis of Transthyretin Amyloid Cardiomyopathy by selective screening in patients undergoing spinal st…
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy [Phase 4]
Phase 4 clinical trial evaluating SGLT2 inhibitors in transthyretin amyloid cardiomyopathy has completed with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: Global Prevalence of ATTR-CM in Participants With HFpEF [NA]
Pfizer-sponsored clinical trial evaluating how common transthyretin amyloid cardiomyopathy is among people with heart failure with preserved…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [Phase 3]
Phase 3 trial of AG10 in transthyretin amyloid cardiomyopathy has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis [Phase 4]
Phase 4 clinical trial evaluating trimetazidine's impact on mitochondrial function, myocardial performance, and invasive hemodynamics in pat…